Amedeo Smart

Free Medical Literature Service

 

Amedeo

Influenza
  Free Subscription

Articles published in
J Infect
    November 2025
  1. CRAWFORD-JONES D, Charlett M, Downs L, Jeffery K, et al
    Real-world utility of antigen-based testing (LumiraDX) for SARS-CoV-2 and influenza A/B in an acute hospital emergency care setting: a useful triage tool.
    J Infect. 2025;91:106649.
    >> Share

    October 2025
  2. HAN S, Liu Y, Xing B, Yang Y, et al
    Association of Glucagon-Like Peptide-1 Receptor Agonist Use with Risk of Infections: A Systematic Review and Meta-analysis.
    J Infect. 2025 Oct 29:106645. doi: 10.1016/j.jinf.2025.106645.
    >> Share

  3. BORROW R, Caugant DA, Clark SA, Dinleyici EC, et al
    Current global trends in meningococcal disease control, risk groups and vaccination: Consensus of the Global Meningococcal Initiative.
    J Infect. 2025 Oct 17:106635. doi: 10.1016/j.jinf.2025.106635.
    >> Share

  4. FOULKES S, Munro K, Sparkes D, Khawam J, et al
    Prevalence and impact of SARS-CoV-2, influenza, respiratory syncytial virus (RSV) infection and respiratory illness on UK healthcare workers during winter 2023/24 (September 2023 to March 2024): SIREN cohort study.
    J Infect. 2025;91:106620.
    >> Share

  5. RAJAN A, Nagaraj D, Bomidi C, Aloisio GM, et al
    Single cell sequencing analysis of respiratory syncytial virus-infected pediatric and adult human nose organoids reveals age differences, proliferative diversity and identifies novel cellular tropism.
    J Infect. 2025;91:106617.
    >> Share

    September 2025
  6. MOORE CM, Secor EA, Fairbanks-Mahnke A, Everman JL, et al
    Independent and interactive effects of viral species on early-life lower respiratory tract illness.
    J Infect. 2025 Sep 25:106616. doi: 10.1016/j.jinf.2025.106616.
    >> Share

  7. GRANVIK C, Persson IL, Barros GWF, Ahlm C, et al
    Long-term Physical Capacity Following COVID-19: A Prospective, Three-Year Study.
    J Infect. 2025 Sep 12:106614. doi: 10.1016/j.jinf.2025.106614.
    >> Share

  8. PRITCHARD E, Vihta KD, Lipworth S, Pouwels KB, et al
    An Electronic Health Record-Wide Association Study to identify populations at increased risk of E. coli bloodstream infections.
    J Infect. 2025 Sep 3:106612. doi: 10.1016/j.jinf.2025.106612.
    >> Share

  9. ATTAIANESE F, Trapani S, Agostiniani R, Ambrosino N, et al
    Effectiveness of a targeted infant RSV immunization strategy (2024-2025): A multicenter matched case-control study in a high-surveillance setting.
    J Infect. 2025;91:106600.
    >> Share

  10. SYMES R, Keddie SH, Walker J, McKeever T, et al
    Burden of respiratory syncytial virus infection in older adults hospitalised in England during 2023/24.
    J Infect. 2025;91:106570.
    >> Share

  11. GONZALEZ-SANCHEZ A, Andres C, Prats-Mendez I, Pinana M, et al
    Evolutionary dynamics of HRSV following the implementation of nirsevimab immunoprophylaxis in Catalonia (2023-2024).
    J Infect. 2025;91:106567.
    >> Share

    August 2025
  12. STANLEY J, Arnold D, Hamilton F
    Genetic evidence supports trialling IL-6 inhibition in influenza.
    J Infect. 2025 Aug 31:106606. doi: 10.1016/j.jinf.2025.106606.
    >> Share

  13. AHIMBISIBWE G, Greenwood D, Wilkinson KA, Gahir J, et al
    Third exposure to COVID-19 infection or vaccination differentially impacts T Cell responses.
    J Infect. 2025 Aug 21:106598. doi: 10.1016/j.jinf.2025.106598.
    >> Share

  14. LIU B, Song S, Liu W, Hu Y, et al
    Post-COVID-19 multimorbidity incidence by prior vaccination status in people with a pre-existing comorbidity: A population-based cohort study.
    J Infect. 2025;91:106597.
    >> Share

  15. SONG X, Hou X, Li Y, Zhang R, et al
    Prevalence and Transmission of Influenza A (H6) Viruses Pose a Potential Threat to Public Health.
    J Infect. 2025 Aug 19:106594. doi: 10.1016/j.jinf.2025.106594.
    >> Share

  16. DIETL B, Henares D, Cuchi E, Blanco-Fuertes M, et al
    Differential nasopharyngeal microbiota patterns: A Comparative Study of Pneumococcal Pneumonia, COVID-19, and Healthy Adults.
    J Infect. 2025 Aug 14:106589. doi: 10.1016/j.jinf.2025.106589.
    >> Share

  17. MCGEOCH LJ, Foulkes S, Whitaker H, Munro K, et al
    Effectiveness of influenza vaccination against infection in UK healthcare workers during winter 2023-24: The SIREN cohort study.
    J Infect. 2025;91:106585.
    >> Share

  18. LI Z, Wang X, Chen S, Xiong W, et al
    Assessing Global Border Controls in Response to COVID-19 Pandemic Using Real-World Data and Target Trial Emulation.
    J Infect. 2025 Aug 12:106578. doi: 10.1016/j.jinf.2025.106578.
    >> Share

  19. JANANI L, Munro APS, Wright A, Aley PK, et al
    Heterologous COVID-19 vaccine schedule with protein-based prime (NVX-CoV2373) and mRNA boost (BNT162b2) induces strong humoral responses: results from COV-BOOST trial.
    J Infect. 2025 Aug 7:106576. doi: 10.1016/j.jinf.2025.106576.
    >> Share

    July 2025
  20. CHRISTIANSEN CH, Sogaard KK, Dam-Dalgeir G, Dessau RB, et al
    Surveillance of invasive beta-haemolytic streptococci in Denmark, 2012 to 2023: A nationwide study.
    J Infect. 2025 Jul 24:106559. doi: 10.1016/j.jinf.2025.106559.
    >> Share

  21. MALLINSON PA, Dasi T, Banjara SK, Lieber J, et al
    Impact of distribution of facemasks on community incidence and outcomes of COVID-19: A cluster randomised trial in India.
    J Infect. 2025 Jul 23:106557. doi: 10.1016/j.jinf.2025.106557.
    >> Share

  22. ZHANG S, Liang H, Xu J, Chen B, et al
    Spatial-temporal Dynamics and Virus Interference of Respiratory Viruses: Insights from Multi-Pathogen Surveillance in China.
    J Infect. 2025 Jul 22:106556. doi: 10.1016/j.jinf.2025.106556.
    >> Share

  23. SAITO R, Chon I, Sato I, Kawashima T, et al
    Impact of polymerase acidic subunit (PA) substitutions on fever and symptoms in pediatric influenza A patients treated with baloxavir: A pooled four-season analysis.
    J Infect. 2025;91:106555.
    >> Share

    June 2025
  24. KALKERI R, Zhu M, Cloney-Clark S, Parekh A, et al
    Anti-Spike IgG4 and Fc Effector Responses: The Impact of SARS-CoV-2 Vaccine Platform-Specific Priming and Immune Imprinting.
    J Infect. 2025 Jun 26:106543. doi: 10.1016/j.jinf.2025.106543.
    >> Share

  25. RIVERA-IZQUIERDO M, Verdejo-Ianez A, Morales-Portillo A, Gonzalez-Alcaide M, et al
    High-dose versus standard-dose influenza vaccine for immunocompromised patients: A systematic review and meta-analysis of randomised clinical trials.
    J Infect. 2025;91:106538.
    >> Share

  26. WANG J, Guo S, Zhao J, Sun T, et al
    Host lncRNA assists the nuclear import of influenza A virus protein PB2 in a species-specific manner.
    J Infect. 2025;91:106540.
    >> Share

  27. YANG J, Chen X, Li X, Zhang Y, et al
    Global spread of H3 subtype avian influenza viruses with an accelerated evolution after interspecies transmission.
    J Infect. 2025 Jun 20:106542. doi: 10.1016/j.jinf.2025.106542.
    >> Share

    May 2025
  28. BREUER J, Drysdale M, Walker J, Han J, et al
    Monitoring the Emergence of Resistance With Sotrovimab in Immunocompromised Patients With COVID-19: LUNAR Study.
    J Infect. 2025 May 19:106510. doi: 10.1016/j.jinf.2025.106510.
    >> Share

  29. PETER RS, Sedelmaier L, Nieters A, Brockmann SO, et al
    Symptom burden and post-COVID-19 syndrome 24 months following SARS-CoV-2 infection: Longitudinal population-based study.
    J Infect. 2025;90:106500.
    >> Share

  30. HOOG M, Westrhenen ESH, Winkel AM, Jong MD, et al
    Impact of co-infection with SARS-CoV-2 and other respiratory viruses on illness: Pooled analyses of 11 COVID-19 cohorts.
    J Infect. 2025 May 9:106501. doi: 10.1016/j.jinf.2025.106501.
    >> Share

    April 2025
  31. RIEDMANN U, Chalupka A, Richter L, Werber D, et al
    Underlying health biases in previously-infected SARS-CoV-2 vaccination recipients: a cohort study.
    J Infect. 2025 Apr 30:106497. doi: 10.1016/j.jinf.2025.106497.
    >> Share

  32. OVERTON CE, Fyles M, Mellor J, Paton RS, et al
    SARS-CoV-2 test sensitivity and duration of positivity in the UK during the 2023/2024 Winter: A prospective cohort study based on self-reported data.
    J Infect. 2025;90:106485.
    >> Share

  33. CHEN R, Hao Z, Ye J, Zhao X, et al
    Decoding Post-Mortem Infection Dynamics of SARS-CoV-2, IAV and RSV: New Insights for Public Health and Emerging Infectious Diseases Management.
    J Infect. 2025 Apr 21:106489. doi: 10.1016/j.jinf.2025.106489.
    >> Share

  34. WADIA U, Moore HC, Richmond PC, Levy A, et al
    Effectiveness of nirsevimab in preventing RSV-hospitalisation among young children in Western Australia 2024.
    J Infect. 2025;90:106466.
    >> Share

    March 2025
  35. JIN R, Qin T, Li P, Yuan J, et al
    Increased Circulation of Adenovirus in China During 2023-2024: Association with an Increased Prevalence of Species B and School-Associated Transmission.
    J Infect. 2025 Mar 21:106475. doi: 10.1016/j.jinf.2025.106475.
    >> Share

  36. CARSTENS G, Kozanli E, Bulsink K, McDonald S, et al
    Co-infection dynamics of SARS-CoV-2 and respiratory viruses in the 2022/2023 respiratory season in the Netherlands.
    J Infect. 2025 Mar 21:106474. doi: 10.1016/j.jinf.2025.106474.
    >> Share

  37. PEREZ CM, Ruiz-Rius S, Ramirez-Morros A, Vidal M, et al
    Post-vaccination IgG4 and IgG2 class switch associates with increased risk of SARS-CoV-2 infections.
    J Infect. 2025 Mar 18:106473. doi: 10.1016/j.jinf.2025.106473.
    >> Share

  38. ZHAO J, Sheng G, Lyu Y, Sun Y, et al
    Oral ADC189 for Adults and Adolescents with Uncomplicated Influenza.
    J Infect. 2025 Mar 13:106472. doi: 10.1016/j.jinf.2025.106472.
    >> Share

  39. WARD T, Paton RS, Overton CE, Mellor J, et al
    Understanding the Effectiveness of the Comirnaty Monovalent and Bivalent Vaccines During the Winter Coronavirus (COVID-19) Infection Survey.
    J Infect. 2025 Mar 5:106461. doi: 10.1016/j.jinf.2025.106461.
    >> Share

  40. YANG J, Zheng S, Sun J, Wu H, et al
    A human-infecting H10N5 avian influenza virus: clinical features, virus reassortment, receptor-binding affinity, and possible transmission routes.
    J Infect. 2025 Mar 4:106456. doi: 10.1016/j.jinf.2025.106456.
    >> Share

  41. FENG Q, Wang J, Wang X, Tian J, et al
    Clinical epidemiological characteristics of hospitalized pediatric viral community-acquired pneumonia in China.
    J Infect. 2025;90:106450.
    >> Share

  42. LIANG C, Begier E, Hagel S, Ankert J, et al
    Incidence of RSV-related hospitalizations for ARIs, including CAP: Data from the German prospective ThEpiCAP study.
    J Infect. 2025;90:106440.
    >> Share

    February 2025
  43. SONG Y, Gong YN, Chen KF, Smith DK, et al
    Global epidemiology, seasonality and climatic drivers of the four human parainfluenza virus types.
    J Infect. 2025 Feb 26:106451. doi: 10.1016/j.jinf.2025.106451.
    >> Share

  44. MAZARAKIS N, Toh ZQ, Neal E, Bright K, et al
    The immunogenicity, reactogenicity, and safety of a bivalent mRNA or protein COVID-19 vaccine given as a fourth dose.
    J Infect. 2025 Feb 18:106447. doi: 10.1016/j.jinf.2025.106447.
    >> Share

  45. WILLIAMS KV, Krauland MG, Nowalk MP, Harrison LH, et al
    Increasing child vaccination coverage can reduce influenza cases across age groups: An agent-based modeling study.
    J Infect. 2025;90:106443.
    >> Share

  46. NOBLE C, McDonald E, Nicholson S, Biering-Sorensen S, et al
    Characterising the SARS-CoV-2 nucleocapsid (N) protein antibody response.
    J Infect. 2025 Feb 6:106436. doi: 10.1016/j.jinf.2025.106436.
    >> Share

    January 2025
  47. QUINT JK, Dube S, Carty L, Yokota R, et al
    Immunocompromised individuals remain at risk of COVID-19: 2023 results from the observational INFORM study.
    J Infect. 2025 Jan 29:106432. doi: 10.1016/j.jinf.2025.106432.
    >> Share

  48. BENNETT C, Chau G, Clayton E, Chu L, et al
    Safety and Immunogenicity of Omicron Protein Vaccines in mRNA-Vaccinated Adolescents: A Phase 3, Randomised Trial.
    J Infect. 2025 Jan 26:106428. doi: 10.1016/j.jinf.2025.106428.
    >> Share

  49. FENG S, Bibi S, Aley PK, Cappuccini F, et al
    Safety and humoral immunogenicity of the ChAdOx1 nCoV-19 vaccine administered as a fourth dose booster following two doses of ChAdOx1 nCoV-19 and a third dose of BNT162b2 (COV009): A prospective cohort study.
    J Infect. 2025;90:106423.
    >> Share

  50. ROMERO-RAMIREZ A, Somasundaran A, Kontogianni K, Parkes J, et al
    Evaluation of the diagnostic accuracy of Xpert(R) Mpox and STANDARD M10 MPX/OPX for the detection of monkeypox virus.
    J Infect. 2025 Jan 15:106413. doi: 10.1016/j.jinf.2025.106413.
    >> Share

  51. WENDEL-GARCIA PD, Ceccato A, Motos A, Franch-Llasat D, et al
    Empirical antibiotic therapy improves outcomes in mechanically ventilated patients with COVID-19: An emulated targeted trial within a prospective, multicentre cohort study.
    J Infect. 2025 Jan 13:106411. doi: 10.1016/j.jinf.2025.106411.
    >> Share

  52. RJOOB K, Antonelli M, Murray B, Molteni E, et al
    Symptom Evolution in Individuals with Ongoing Symptomatic COVID-19 and Post COVID-19 Syndrome After SARS-CoV-2 Vaccination Versus Influenza Vaccination.
    J Infect. 2025 Jan 10:106406. doi: 10.1016/j.jinf.2024.106406.
    >> Share

  53. NURMI V, Mayne R, Knight C, Almonacid-Mendoza HL, et al
    Individual patient and donor seroprofiles in convalescent plasma treatment of COVID-19 in REMAP-CAP clinical trial.
    J Infect. 2025 Jan 9:106412. doi: 10.1016/j.jinf.2025.106412.
    >> Share

  54. ONG DS, Harris M, Hart JD, Russell FM, et al
    Lack of correlation between school reopening and trends in adult COVID-19 hospitalisations and death rates during the Delta and early Omicron periods: an ecological analysis of five countries.
    J Infect. 2025 Jan 6:106390. doi: 10.1016/j.jinf.2024.106390.
    >> Share

  55. JORDA A, Prager M, Pracher L, Haselwanter P, et al
    Immunogenicity, Safety, and Reactogenicity of Concomitant Administration of the Novavax Vaccine against Omicron XBB.1.5 (NVX-CoV2601) and a 20-valent Pneumococcal Conjugate Vaccine in Adults Aged >/=60 Years: A Randomised, Double-blind, Placebo-contro
    J Infect. 2025 Jan 3:106405. doi: 10.1016/j.jinf.2024.106405.
    >> Share

    December 2024
  56. RUBIO R, Yavlinsky A, Zamudio ME, Molinos-Albert LM, et al
    Initial antigen encounter determines robust T-cell immunity against SARS-CoV-2 BA.2.86 variant three years later.
    J Infect. 2024 Dec 31:106402. doi: 10.1016/j.jinf.2024.106402.
    >> Share

  57. MENSAH AA, Stowe J, Brown K, LopezBernal J, et al
    COVID-19 reinfection in pregnancy: assessment of Severity and pregnancy outcomes in England.
    J Infect. 2024 Dec 27:106392. doi: 10.1016/j.jinf.2024.106392.
    >> Share

  58. MONK EJM, Foulkes S, Munro K, Atti A, et al
    Characterisation of the SARS-CoV-2 pandemic in healthcare workers within the United Kingdom: risk factors for infection during four successive waves.
    J Infect. 2024 Dec 27:106393. doi: 10.1016/j.jinf.2024.106393.
    >> Share

  59. MOK CKP, Tang YS, Tan CW, Chong KC, et al
    Comparison of safety and immunogenicity in the elderly after receiving either Comirnaty or Spikevax monovalent XBB1.5 COVID-19 vaccine.
    J Infect. 2024;90:106374.
    >> Share

  60. CITRON MP, Zang X, Leithead A, Meng S, et al
    Evaluation of a non-nucleoside inhibitor of the RSV RNA-dependent RNA polymerase in translatable animals models.
    J Infect. 2024;89:106325.
    >> Share

  61. ALOISIO GM, Nagaraj D, Murray AM, Schultz EM, et al
    Infant-derived human nasal organoids exhibit relatively increased susceptibility, epithelial responses, and cytotoxicity during RSV infection.
    J Infect. 2024;89:106305.
    >> Share

    November 2024
  62. LUO H, Cui Y, Yu W, Li G, et al
    The impact of urbanization in China on influenza incidence across neighboring cities.
    J Infect. 2024 Nov 28:106370. doi: 10.1016/j.jinf.2024.106370.
    >> Share

  63. JIA T, Wang F, Chen Y, Liao G, et al
    Expanded immune imprinting and neutralization spectrum by hybrid immunization following breakthrough infections with SARS-CoV-2 variants after three-dose vaccination.
    J Infect. 2024 Nov 26:106362. doi: 10.1016/j.jinf.2024.106362.
    >> Share

  64. CHOW KN, Tsang YW, Chan YH, Telaga SA, et al
    The effect of pre-COVID and post-COVID vaccination on long COVID: a systematic review and meta-analysis.
    J Infect. 2024 Nov 21:106358. doi: 10.1016/j.jinf.2024.106358.
    >> Share

  65. REN Z, Yang M, Su G, Qian G, et al
    Real-world effectiveness and safety of Azvudine in hospitalized patients with SARS-CoV-2 infection: a multicenter, retrospective cohort study.
    J Infect. 2024 Nov 17:106355. doi: 10.1016/j.jinf.2024.106355.
    >> Share

  66. LIU Q, Zhong P, Wei Q, Wang X, et al
    Mechanisms of MHC-II Binding by Novel Influenza A Viruses and Their Cross-Species Transmission Potential.
    J Infect. 2024 Nov 16:106354. doi: 10.1016/j.jinf.2024.106354.
    >> Share

  67. MCLEOD C, Dymock M, Flanagan KL, Plebanski M, et al
    The Platform Trial In COVID-19 priming and BOOsting (PICOBOO): the immunogenicity, reactogenicity, and safety of licensed COVID-19 vaccinations administered as a second booster in BNT162b2 primed individuals aged 18-<50 and 50-<70 years old.
    J Infect. 2024 Nov 14:106346. doi: 10.1016/j.jinf.2024.106346.
    >> Share

  68. HAN B, Du C, Deng M, Tang R, et al
    Real-world effectiveness and safety of simnotrelvir/ritonavir for COVID-19: A nationwide, multicenter, prospective, observational cohort study in China.
    J Infect. 2024 Nov 7:106339. doi: 10.1016/j.jinf.2024.106339.
    >> Share

  69. DULFER EA, Fohse K, Taks EJM, Moorlag SJCFM, et al
    The effect of BCG vaccination in the elderly on infectious and non-infectious immune-mediated diseases.
    J Infect. 2024;89:106344.
    >> Share

  70. HO A, McInnes N, Blunsum A, Quinn J, et al
    Near real-time severe acute respiratory illness surveillance characterising influenza and COVID-19 epidemiology in hospitalised adults, 2021-22.
    J Infect. 2024;89:106338.
    >> Share

    October 2024
  71. WANG H, Zhou Y, Chu L, Chen K, et al
    Guardian-driven influenza vaccination intentions for children post-COVID-19 in the 2024-2025 season: The positive spillover effects.
    J Infect. 2024;89:106333.
    >> Share

  72. KUMAR NP, Balaji S, Devi PG, Ramraj B, et al
    Inflammatory Cytokine Responses in Pediatric tuberculosis with or without SARS-CoV-2 seropositivity.
    J Infect. 2024 Oct 17:106314. doi: 10.1016/j.jinf.2024.106314.
    >> Share

  73. WEI X, Wang L, Li M, Qi J, et al
    Novel imported clades accelerated the RSV surge in Beijing, China, 2023-2024.
    J Infect. 2024 Oct 17:106321. doi: 10.1016/j.jinf.2024.106321.
    >> Share

  74. MEIRMAN TD, Shapira B, Balicer RD, Rokach L, et al
    Trends of Common Laboratory Biomarkers after SARS-CoV-2 Infection.
    J Infect. 2024 Oct 16:106318. doi: 10.1016/j.jinf.2024.106318.
    >> Share

  75. CHEN X, Meng X, Wu Q, Lim WW, et al
    Assessment of Neutralizing Antibody Response as a Correlate of Protection against Symptomatic SARS-CoV-2 Infections after Administration of two doses of the CoronaVac inactivated COVID-19 Vaccine: A Phase III Randomized Controlled Trial.
    J Infect. 2024 Oct 16:106315. doi: 10.1016/j.jinf.2024.106315.
    >> Share

  76. MADSEN AMR, Gehrt L, Schaltz-Buchholzer F, Moller S, et al
    Evaluating the effect of BCG vaccination for non-specific protection from infection in senior citizens during the COVID-19 pandemic: a randomised clinical trial.
    J Infect. 2024 Oct 16:106319. doi: 10.1016/j.jinf.2024.106319.
    >> Share

  77. MARCHESE AM, Fries L, Beyhaghi H, Vadivale M, et al
    Mechanisms and Implications of IgG4 Responses to SARS-CoV-2 and Other Repeatedly Administered Vaccines.
    J Infect. 2024 Oct 15:106317. doi: 10.1016/j.jinf.2024.106317.
    >> Share

  78. LI Y, Zhang X, Yi J, Chen Y, et al
    Synergistic evolution: the dynamic adaptation of SARS-CoV-2 and human protective immunity in the real world.
    J Infect. 2024 Oct 9:106310. doi: 10.1016/j.jinf.2024.106310.
    >> Share

  79. MUSCATELLO DJ, Rose N, Paul KK, Ware S, et al
    Epidemiological comparison of emergency department presentations with seasonal influenza or COVID-19 and an outcome of intensive care admission or death: a population-based records linkage study in New South Wales, Australia.
    J Infect. 2024 Oct 8:106307. doi: 10.1016/j.jinf.2024.106307.
    >> Share

  80. LI Y, Sun Z, Liu X, Wei S, et al
    Highly Pathogenic Avian Influenza A(H5N1) Virus infection in dairy cattle:threat of bird flu has expanded to open-air farmed livestock.
    J Infect. 2024 Oct 7:106311. doi: 10.1016/j.jinf.2024.106311.
    >> Share

  81. AMARILLA-IRUSTA A, Zenarruzabeitia O, Sevilla A, Sanda V, et al
    CD151 identifies a NK cell subset that is enriched in COVID-19 patients and correlates with disease severity.
    J Infect. 2024 Oct 5:106304. doi: 10.1016/j.jinf.2024.106304.
    >> Share

  82. FYLES M, Overton CE, Ward T, Bennett E, et al
    Modelling multiplex testing for outbreak control.
    J Infect. 2024 Oct 1:106303. doi: 10.1016/j.jinf.2024.106303.
    >> Share

    September 2024
  83. AKSU MD, van der Ent T, Zhang Z, Riza AL, et al
    Regulation of plasma soluble receptors of TNF and IL-1 in patients with COVID-19 differs from that observed in sepsis.
    J Infect. 2024 Sep 30:106300. doi: 10.1016/j.jinf.2024.106300.
    >> Share

  84. DEHLIA A, Guthridge MA
    The persistence of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) after SARS-CoV-2 infection: A systematic review and meta-analysis.
    J Infect. 2024 Sep 29:106297. doi: 10.1016/j.jinf.2024.106297.
    >> Share

  85. KIRWAN PD, Foulkes S, Munro K, Sparkes D, et al
    Protection of vaccine boosters and prior infection against mild/asymptomatic and moderate COVID-19 infection in the UK SIREN healthcare worker cohort: October 2023 to March 2024.
    J Infect. 2024 Sep 27:106293. doi: 10.1016/j.jinf.2024.106293.
    >> Share

  86. MAZZOTTA V, Mazzaferri F, Lanini S, Mirandola M, et al
    Pooled analysis of the MANTICO2 and MONET randomized controlled trials comparing drug efficacy for early treatment of COVID-19 during Omicron waves.
    J Infect. 2024 Sep 27:106294. doi: 10.1016/j.jinf.2024.106294.
    >> Share

  87. BENNETT C, Hoosain Z, Koen A, Lalloo U, et al
    Immunogenicity and Safety of SARS-CoV-2 Recombinant Spike Protein Vaccine in South African People Living With and Without HIV-1 Infection: A Phase 2 Randomised Trial.
    J Infect. 2024 Sep 27:106285. doi: 10.1016/j.jinf.2024.106285.
    >> Share

  88. VEGA-PIRIS L, Carretero SG, Mayordomo JL, Zarzuelo MBR, et al
    Severity of Respiratory Syncytial Virus compared with SARS-CoV-2 and Influenza among hospitalised adults >/=65 years.
    J Infect. 2024 Sep 26:106292. doi: 10.1016/j.jinf.2024.106292.
    >> Share

  89. RABDANO SO, Ruzanova EA, Vertyachikh AE, Teplykh VA, et al
    N-protein vaccine is effective against COVID-19: phase 3, randomized, double-blind, placebo-controlled clinical trial.
    J Infect. 2024 Sep 26:106288. doi: 10.1016/j.jinf.2024.106288.
    >> Share

  90. CHEN X, Balliew J, Bauer CX, Deegan J, et al
    Revealing patterns of SARS-CoV-2 variant emergence and evolution using RBD amplicon sequencing of wastewater.
    J Infect. 2024 Sep 26:106284. doi: 10.1016/j.jinf.2024.106284.
    >> Share

  91. SABATE-ELABBADI A, Brolon L, Brun-Buisson C, Guillemot D, et al
    Trends in hospitalisations for lower respiratory infections after the COVID-19 pandemic in France.
    J Infect. 2024 Sep 26:106287. doi: 10.1016/j.jinf.2024.106287.
    >> Share

  92. MCLEOD C, Dymock, Flanagan KL, Plebanski M, et al
    The Platform Trial In COVID-19 Priming and BOOsting (PICOBOO): the immunogenicity, reactogenicity, and safety of different COVID-19 vaccinations administered as a second booster (fourth dose) in AZD1222 primed individuals aged 50-<70 years old.
    J Infect. 2024 Sep 26:106286. doi: 10.1016/j.jinf.2024.106286.
    >> Share

  93. CHRISTENSEN J, Johansen ND, Janstrup KH, Modin D, et al
    Time of day for vaccination, outcomes, and relative effectiveness of high-dose vs. standard-dose quadrivalent influenza vaccine: a post-hoc analysis of the DANFLU-1 randomized clinical trial.
    J Infect. 2024 Sep 18:106276. doi: 10.1016/j.jinf.2024.106276.
    >> Share

  94. SKAARUP KG, Lassen MCH, Modin D, Johansen ND, et al
    Corrigendum to "The relative vaccine effectiveness of high-dose vs standard-dose influenza vaccines in preventing hospitalization and mortality: A meta-analysis of evidence from randomized trials" [J Infect 89 (2024) 106187].
    J Infect. 2024;89:106270.
    >> Share

  95. MCDONALD E, Pittet LF, Barry SE, Bonten M, et al
    Antecedent and persistent symptoms in COVID-19 and other respiratory illnesses: insights from prospectively collected data in the BRACE trial.
    J Infect. 2024 Sep 6:106267. doi: 10.1016/j.jinf.2024.106267.
    >> Share

  96. CHAPMAN ME, Brendish NJ, Morris M, Spalluto CM, et al
    Real-world performance of a single-use, analyser-free, molecular point-of-care test for COVID-19 used in the emergency department: results of a prospective trial (ED-POC).
    J Infect. 2024 Sep 5:106264. doi: 10.1016/j.jinf.2024.106264.
    >> Share

    August 2024
  97. AZIZ AB, Sugimoto JD, Hong SL, You YA, et al
    Indirect effectiveness of a novel SAR-COV-2 vaccine (SCB-2019) in unvaccinated household contacts in the Philippines: a cluster randomised analysis.
    J Infect. 2024 Aug 30:106260. doi: 10.1016/j.jinf.2024.106260.
    >> Share

  98. GRAM MA, Thiesson EM, Pihlstrom N, Perala J, et al
    Comparative effectiveness of bivalent BA.4-5 or BA.1 mRNA booster vaccines among immunocompromised individuals across three Nordic countries: A nationwide cohort study.
    J Infect. 2024;89:106261.
    >> Share

  99. HASAN T, Zhu NJ, Pearson C, Aylin P, et al
    Increased 30-day all-cause mortality associated with Gram-negative bloodstream infections in England during the COVID-19 pandemic.
    J Infect. 2024 Aug 29:106256. doi: 10.1016/j.jinf.2024.106256.
    >> Share

  100. HOBBS FR, Gbinigie OA, Shanyinde M, Yu LM, et al
    Favipiravir for COVID-19 in adults in the community in PRINCIPLE, an open-label, randomised, controlled, adaptive platform trial of short- and longer-term outcomes.
    J Infect. 2024 Aug 29:106248. doi: 10.1016/j.jinf.2024.106248.
    >> Share

  101. FOULKES S, Evans J, Neill C, Bishop J, et al
    Prevalence and impact of persistent symptoms following SARS-CoV-2 infection among healthcare workers: a cross-sectional survey in the SIREN cohort.
    J Infect. 2024 Aug 28:106259. doi: 10.1016/j.jinf.2024.106259.
    >> Share

  102. GOTTLIEB RL, Clement M, Cook P, Deveikis A, et al
    The IL-6 Hypothesis in COVID-19: A Phase 2, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Free IL-6 Sequestration by the Monoclonal Antibody Sirukumab in Severe and Critical COVID-19.
    J Infect. 2024 Aug 23:106241. doi: 10.1016/j.jinf.2024.106241.
    >> Share

  103. LI Y, Yin Z, Wang J, Xu Y, et al
    Surveillance of avian influenza viruses in Hebei Province of China from 2021 to 2023: identification of a novel reassortant H3N3.
    J Infect. 2024 Aug 20:106240. doi: 10.1016/j.jinf.2024.106240.
    >> Share

  104. FRYER HA, Geers D, Gommers L, Zaeck LM, et al
    Fourth dose bivalent COVID-19 vaccines outperform monovalent boosters in eliciting cross-reactive memory B cells to Omicron subvariants.
    J Infect. 2024 Aug 8:106246. doi: 10.1016/j.jinf.2024.106246.
    >> Share

  105. MESSINA NL, Pittet LF, McDonald E, Moore C, et al
    BCG vaccination of healthcare workers for protection against COVID-19: 12-month outcomes from an international randomised controlled trial.
    J Infect. 2024 Aug 8:106245. doi: 10.1016/j.jinf.2024.106245.
    >> Share

  106. WANG HI, Doran T, Crooks MG, Khunti K, et al
    Prevalence, risk factors and characterisation of individuals with long COVID using Electronic Health Records in over 1.5 million COVID cases in England.
    J Infect. 2024;89:106235.
    >> Share

  107. QUEK AML, Wang S, Teng O, Shunmuganathan B, et al
    Hybrid immunity augments cross-variant protection against COVID-19 among immunocompromised individuals.
    J Infect. 2024 Aug 7:106238. doi: 10.1016/j.jinf.2024.106238.
    >> Share

  108. SILVA-COSTA C, Gomes-Silva J, Pinho M, Friaes A, et al
    Rebound of pediatric invasive pneumococcal disease in Portugal after the COVID-19 pandemic was not associated with significant serotype changes.
    J Infect. 2024 Aug 6:106242. doi: 10.1016/j.jinf.2024.106242.
    >> Share

    July 2024
  109. LI J, Zhang Y, Liu Z, Yang Z, et al
    Increased SARS-CoV-2 reinfection frequency, attenuated severity, and risk factor analysis in patients with hematological malignancies.
    J Infect. 2024;89:106233.
    >> Share

  110. BECHMAN K, Green A, Russell MD, Yang Z, et al
    The safety of antivirals and neutralising monoclonal antibodies used in prehospital treatment of Covid-19.
    J Infect. 2024 Jul 15:106227. doi: 10.1016/j.jinf.2024.106227.
    >> Share

  111. ANDREWS N, Osuntoki I, Stowe J, Kirsebom FCM, et al
    The impact of Covid-19 vaccine spring boosters on Covid-19 hospital admissions in England 2022/23.
    J Infect. 2024 Jul 10:106221. doi: 10.1016/j.jinf.2024.106221.
    >> Share

  112. KADAMBARI S, Abdullahi F, Celma C, Ladhani S, et al
    Epidemiological trends in viral meningitis in England: prospective national surveillance, 2013-2023.
    J Infect. 2024 Jul 8:106223. doi: 10.1016/j.jinf.2024.106223.
    >> Share

  113. STARKE KR, Kaboth P, Rath N, Reissig D, et al
    Cardiovascular disease risk after a SARS-CoV-2 infection: a systematic review and meta-analysis.
    J Infect. 2024 Jul 4:106215. doi: 10.1016/j.jinf.2024.106215.
    >> Share

  114. HALME ALE, Laakkonen S, Rutanen J, Nevalainen OPO, et al
    Short- and long-term effects of imatinib in hospitalised COVID-19 patients: A randomised trial.
    J Infect. 2024 Jul 3:106217. doi: 10.1016/j.jinf.2024.106217.
    >> Share

  115. MOKRANI D, Le Hingrat Q, Thy M, Choquet C, et al
    Clinical characteristics and outcomes of respiratory syncytial virus-associated ARF in immunocompetent patients: A seven-year experience at a tertiary hospital in France.
    J Infect. 2024;89:106180.
    >> Share

    June 2024
  116. BOOM TT, de Hoog MLA, Westerhof I, Jaddoe V, et al
    Age-specific SARS-CoV-2 transmission differed from human rhinovirus in households during the early COVID-19 pandemic.
    J Infect. 2024 Jun 29:106218. doi: 10.1016/j.jinf.2024.106218.
    >> Share

  117. BOYS R, Plank J, Bird P, Fletcher O, et al
    Impact of COVID-19 restrictions on the incidence of respiratory viruses in two British Antarctic Survey bases.
    J Infect. 2024;89:106196.
    >> Share

  118. DU Z, Wang S, Chen R, Shan S, et al
    Efficacy and safety of respiratory syncytial virus prefusion F protein vaccines in adults.
    J Infect. 2024;89:106211.
    >> Share

  119. CHAKA A, Pan D, Irshad M, Piranie H, et al
    Inclusion of racial and ethnic groups in clinical trials for COVID-19 and post-acute COVID-19 syndrome: an analysis of studies registered on ClinicalTrials.gov.
    J Infect. 2024 Jun 20:106207. doi: 10.1016/j.jinf.2024.106207.
    >> Share

  120. GONG X, Peng L, Wang F, Liu J, et al
    Repeated Omicron infection dampens immune imprinting from previous vaccination and induces broad neutralizing antibodies against Omicron sub-variants.
    J Infect. 2024;89:106208.
    >> Share

  121. PEREZ-GARCIA C, Sempere J, de Miguel S, Hita S, et al
    Surveillance of invasive pneumococcal disease in Spain exploring the impact of the COVID-19 pandemic (2019-2023).
    J Infect. 2024;89:106204.
    >> Share

  122. ZHAI K, Dong J, Zeng J, Cheng P, et al
    Global Antigenic Landscape and Vaccine Recommendation Strategy for Low Pathogenic Avian Influenza A(H9N2) Viruses.
    J Infect. 2024 Jun 18:106199. doi: 10.1016/j.jinf.2024.106199.
    >> Share

  123. LIU B, Xu L, Ma Y, Wang H, et al
    Evidence of immunity gap: Decline in antibodies against M. pneumoniae during the COVID-19 pandemic.
    J Infect. 2024 Jun 18:106209. doi: 10.1016/j.jinf.2024.106209.
    >> Share

  124. KAJIHARA T, Yahara K, Kamigaki T, Hirabayashi A, et al
    Effects of coronavirus disease 2019 on the spread of respiratory-transmitted human-to-human bacteria.
    J Infect. 2024 Jun 17:106201. doi: 10.1016/j.jinf.2024.106201.
    >> Share

  125. MIKOLAJCZYK R, Diexer S, Klee B, Pfrommer L, et al
    Likelihood of Post-COVID Condition in people with hybrid immunity; data from the German National Cohort (NAKO).
    J Infect. 2024 Jun 17:106206. doi: 10.1016/j.jinf.2024.106206.
    >> Share

  126. JIANG J, Li Y, Jiang Q, Jiang Y, et al
    Early use of oral antiviral drugs and the risk of post COVID-19 syndrome: a systematic review and network meta-analysis.
    J Infect. 2024 Jun 2:106190. doi: 10.1016/j.jinf.2024.106190.
    >> Share

  127. PATERNINA-CAICEDO A, Quevedo DS, Rios DS, Moyano D, et al
    Heterologous and BNT162b2 boosters are more effective than non-mRNA homologous boosters for Omicron.
    J Infect. 2024;88:106165.
    >> Share

  128. CAI J, Lai L, Li R, Lin Q, et al
    The H5 subtype of avian influenza virus jumped across species to humans - a view from China.
    J Infect. 2024 Jun 1:106193. doi: 10.1016/j.jinf.2024.106193.
    >> Share

    May 2024
  129. SKAARUP KG, Lassen MCH, Modin D, Johansen ND, et al
    The relative vaccine effectiveness of high-dose vs standard-dose influenza vaccines in preventing hospitalization and mortality: A meta-analysis of evidence from randomized trials.
    J Infect. 2024;89:106187.
    >> Share

  130. HAN B, Li XM, Li R, Ning W, et al
    Epidemiological Surveillance of Acute Respiratory Infections Based on Targeted Metagenomic Next Generation Sequencing During the Flu Season after COVID-19 Pandemic in Beijing.
    J Infect. 2024 May 22:106188. doi: 10.1016/j.jinf.2024.106188.
    >> Share

  131. YANG X, Li X, Qiu S, Liu C, et al
    Global antimicrobial resistance and antibiotic use in COVID-19 patients within health facilities: a systematic review and meta-analysis of aggregated participant data.
    J Infect. 2024 May 14:106183. doi: 10.1016/j.jinf.2024.106183.
    >> Share

  132. AMANO M, Ichikawa Y, Matsumoto S, Higashi-Kuwata N, et al
    Neutralization activity of HCWs' sera after Omicron XBB.1.5-adapted monovalent COVID-19 mRNA vaccination.
    J Infect. 2024;89:106179.
    >> Share

  133. KIRSEBOM FCM, Stowe J, Lopez Bernal J, Allen A, et al
    Effectiveness of Autumn 2023 COVID-19 vaccination and residual protection of prior doses against hospitalisation in England, estimated using a test-negative case-control study.
    J Infect. 2024 May 6:106177. doi: 10.1016/j.jinf.2024.106177.
    >> Share

  134. HALVORSEN B, Viermyr HK, Ueland T, Sagen EL, et al
    IL-22 is increased in hospitalized patients with COVID-19 and associates with cardiac involvement.
    J Infect. 2024 May 6:106176. doi: 10.1016/j.jinf.2024.106176.
    >> Share

  135. CAINI S, Casalegno JS, Rodrigues AP, Lee V, et al
    Change in Age profile of Respiratory Syncytial Virus disease over the course of annual epidemics: a multi-national study.
    J Infect. 2024;88:106154.
    >> Share

    April 2024
  136. CANE J, Sanderson N, Barnett S, Vaughan A, et al
    Nanopore sequencing of influenza A and B in Oxfordshire and the United Kingdom, 2022-23.
    J Infect. 2024 Apr 29:106164. doi: 10.1016/j.jinf.2024.106164.
    >> Share

  137. CHUN JY, Jeong SJ, Kim S, Choi S, et al
    Performance of the Galactomannan Test for the Diagnosis of Invasive Pulmonary Aspergillosis using Non-invasive Proximal Airway Samples.
    J Infect. 2024 Apr 17:106159. doi: 10.1016/j.jinf.2024.106159.
    >> Share

  138. PINANA M, Gonzalez-Sanchez A, Andres C, Vila J, et al
    Genomic evolution of human respiratory syncytial virus during a decade (2013-2023): bridging the path to monoclonal antibody surveillance.
    J Infect. 2024 Apr 6:106153. doi: 10.1016/j.jinf.2024.106153.
    >> Share

  139. COLSON P, Chaudet H, Delerce J, Pontarotti P, et al
    Role of SARS-CoV-2 mutations in the evolution of the COVID-19 pandemic.
    J Infect. 2024 Apr 1:106150. doi: 10.1016/j.jinf.2024.106150.
    >> Share

    March 2024
  140. GAYLIS NB, Yang OO
    Understanding immune dysregulation in post-acute sequelae of COVID-19 (PASC) - The hunt for effective treatments.
    J Infect. 2024 Mar 24:106146. doi: 10.1016/j.jinf.2024.106146.
    >> Share

  141. SALMAN M, Rana MS, Usman M, Tahir M, et al
    Re-emergence of Diphtheria after COVID-19 Pandemic in Pakistan: time to consider booster vaccination strategies.
    J Infect. 2024 Mar 19:106141. doi: 10.1016/j.jinf.2024.106141.
    >> Share

  142. SUN L, Man Q, Zhang H, Xia S, et al
    Strong cross immune responses against sarbecoviruses but not merbecoviruses in SARS-CoV-2 BA.5/BF.7-infected individuals with or without inactivated COVID-19 vaccination.
    J Infect. 2024;88:106138.
    >> Share

  143. MORENO-TORRES V, Martinez-Urbistondo M, Calderon-Parra J, de Mendoza C, et al
    COVID-19 Mortality Amongst the Immunosuppresed.
    J Infect. 2024 Mar 11:106137. doi: 10.1016/j.jinf.2024.106137.
    >> Share

  144. FATLY ZA, Betjes MGH, Dik WA, Fouchier RAM, et al
    Mycophenolate mofetil hampers antibody responses to a broad range of vaccinations in kidney transplant recipients: results from a randomized controlled study.
    J Infect. 2024 Mar 1:106133. doi: 10.1016/j.jinf.2024.106133.
    >> Share

  145. POWELL AA, Dowell AC, Moss P, Ladhani SN, et al
    Current state of COVID-19 in children: 4 years on.
    J Infect. 2024 Mar 1:106134. doi: 10.1016/j.jinf.2024.106134.
    >> Share

    February 2024
  146. LIU P, Cai J, Tian H, Li J, et al
    Intra-host genetic diversity of SARS-CoV-2 Omicron variants in children.
    J Infect. 2024 Feb 29:106132. doi: 10.1016/j.jinf.2024.106132.
    >> Share

  147. MEERAUS W, Joy M, Ouwens M, Taylor KS, et al
    AZD1222 effectiveness against severe COVID-19 in individuals with comorbidity or frailty: the RAVEN cohort study.
    J Infect. 2024 Feb 29:106129. doi: 10.1016/j.jinf.2024.106129.
    >> Share

  148. HAYWARD G, Yu LM, Little P, Gbinigie O, et al
    Ivermectin for COVID-19 in adults in the community (PRINCIPLE): an open, randomised, controlled, adaptive platform trial of short- and longer-term outcomes.
    J Infect. 2024 Feb 29:106130. doi: 10.1016/j.jinf.2024.106130.
    >> Share

  149. ZHOU J, Lan L, Ai S, Lin J, et al
    People Living with HIV who have poor immune status are a key population for SARS-CoV-2 prevention.
    J Infect. 2024 Feb 15:106122. doi: 10.1016/j.jinf.2024.106122.
    >> Share

  150. HITES M, Massonnaud CR, Jamard S, Goehringer F, et al
    Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): a phase 3, randomized, double-blind, placebo-controlled trial.
    J Infect. 2024 Feb 15:106120. doi: 10.1016/j.jinf.2024.106120.
    >> Share

  151. YAO Z, Zhang L, Duan Y, Tang X, et al
    Molecular Insights into the Adaptive Evolution of SARS-CoV-2 Spike Protein.
    J Infect. 2024 Feb 15:106121. doi: 10.1016/j.jinf.2024.106121.
    >> Share

  152. KALKERI R, Zhu M, Cloney-Clark S, Plested JS, et al
    Altered IgG4 Antibody Response to Repeated mRNA versus Recombinant Protein SARS-CoV-2 Vaccines.
    J Infect. 2024 Feb 13:106119. doi: 10.1016/j.jinf.2024.106119.
    >> Share

  153. XIE L, Luo G, Yang Z, Wu WC, et al
    The clinical outcome of COVID-19 is strongly associated with microbiome dynamics in the upper respiratory tract.
    J Infect. 2024 Feb 9:S0163-4453(24)00036-7. doi: 10.1016/j.jinf.2024.
    >> Share

  154. HUNG KC, Chen IW, Sun CK
    Pulmonary dysfunction severity may impact optimal dexamethasone dosing in patients with COVID-19.
    J Infect. 2024 Feb 1:S0163-4453(24)00031-8. doi: 10.1016/j.jinf.2024.
    >> Share

    January 2024
  155. LESTON M, Elson W, Ordonez-Mena JM, Kar D, et al
    Disparities in COVID-19 Mortality Amongst the Immunosuppressed: A Systematic Review and Meta-analysis for Enhanced Disease Surveillance.
    J Infect. 2024 Jan 30:S0163-4453(24)00028-8. doi: 10.1016/j.jinf.2024.
    >> Share

  156. KE YK, Han XY, Lin SR, Wu HG, et al
    Emergence of a triple reassortment avian influenza virus (A/H5N6) from wild birds.
    J Infect. 2024 Jan 17:S0163-4453(24)00024-0. doi: 10.1016/j.jinf.2024.
    >> Share

  157. MURRAY JM, Murray DD, Schvoerer E, Akand EH, et al
    SARS-CoV-2 Delta and Omicron community transmission networks as added value to contact tracing.
    J Infect. 2024 Jan 17:S0163-4453(24)00023-9. doi: 10.1016/j.jinf.2024.
    >> Share

  158. CORNISH EF, van der Meeren LE, van der Hoorn MP, Schoenmakers S, et al
    Stillbirths due to placental COVID infection associated with chronic histiocytic intervillositis do not recur in subsequent pregnancies.
    J Infect. 2024 Jan 11:S0163-4453(24)00020-3. doi: 10.1016/j.jinf.2024.
    >> Share

  159. ZHANG H, Zhou K, Peng F, Gao Z, et al
    Novel small-molecule inhibitors of SARS-CoV-2 main protease with nanomolar antiviral potency.
    J Infect. 2024 Jan 6:S0163-4453(23)00600-X. doi: 10.1016/j.jinf.2023.
    >> Share

    December 2023
  160. ZONG K, Yuan P, Wang R, Luo Q, et al
    Characteristics of innate, humoral and cellular immunity in children with non-severe SARS-CoV-2 infection.
    J Infect. 2023 Dec 13:S0163-4453(23)00589-3. doi: 10.1016/j.jinf.2023.
    >> Share

  161. FERNANDEZ-DE-LAS-PENAS C, Notarte KI, Macasaet R, Velasco JV, et al
    Persistence of post-COVID symptoms in the general population two years after SARS-CoV-2 infection: A systematic review and meta-analysis.
    J Infect. 2023 Dec 13:S0163-4453(23)00590-X. doi: 10.1016/j.jinf.2023.
    >> Share

  162. STRAHM C, Kahlert CR, Gusewell S, Vuichard-Gysin D, et al
    Evolution of symptoms compatible with post-acute sequelae of SARS-CoV-2 (PASC) after Wild-type and/or Omicron BA.1 infection: A prospective healthcare worker cohort.
    J Infect. 2023 Dec 7:S0163-4453(23)00588-1. doi: 10.1016/j.jinf.2023.
    >> Share

  163. PAN D, Hui DSC, Tang JW
    Defining infection transmission pathways for future pandemic preparedness - An urgent public health research priority.
    J Infect. 2023;87:595-597.
    >> Share

  164. AO G, Li T, Nasr B, Wang Y, et al
    The effect of dupilumab on clinical outcomes in patients with COVID-19: A meta-analysis.
    J Infect. 2023;87:e107-e109.
    >> Share

  165. LIU Y, Sun R, Zhang H, Huang J, et al
    Trends and predictions of tuberculosis notification in mainland China during and after the COVID-19 pandemic.
    J Infect. 2023;87:e100-e103.
    >> Share

    November 2023
  166. PHAN J, Eslick GD, Elliott EJ
    Demystifying the global outbreak of severe acute hepatitis of unknown aetiology in children: A systematic review and meta-analysis.
    J Infect. 2023 Nov 24:S0163-4453(23)00580-7. doi: 10.1016/j.jinf.2023.
    >> Share

  167. GRAU S, Vela JM, Gurt A, Barcelo-Vidal J, et al
    Efficacy of SIGMAR1-based therapy in the early treatment of confirmed mild symptomatic COVID-19 patients.
    J Infect. 2023 Nov 20:S0163-4453(23)00562-5. doi: 10.1016/j.jinf.2023.
    >> Share

  168. DIEP AN, Schyns J, Gourzones C, Goffin E, et al
    How do successive vaccinations and SARS-CoV-2 infections impact humoral immunity dynamics: an 18-month longitudinal study.
    J Infect. 2023 Nov 17:S0163-4453(23)00558-3. doi: 10.1016/j.jinf.2023.
    >> Share

  169. BRENDISH NJ, Davis C, Chapman ME, Borca F, et al
    Emergency Department point-of-care antiviral host response testing is accurate during periods of multiple respiratory virus co-circulation.
    J Infect. 2023 Nov 15:S0163-4453(23)00556-X. doi: 10.1016/j.jinf.2023.
    >> Share

  170. LIECHTI FD, Bijlsma MW, Brouwer MC, van Sorge NM, et al
    Impact of the COVID-19 pandemic on incidence and serotype distribution of pneumococcal meningitis - A prospective, nationwide cohort study from the Netherlands.
    J Infect. 2023 Nov 8:S0163-4453(23)00555-8. doi: 10.1016/j.jinf.2023.
    >> Share

  171. HALL VJ, Insalata F, Foulkes S, Kirwan P, et al
    Effectiveness of BNT162b2 mRNA vaccine third doses and previous infection in protecting against SARS-CoV-2 infections during the Delta and Omicron variant waves; the UK SIREN cohort study September 2021 to February 2022.
    J Infect. 2023 Nov 3:S0163-4453(23)00553-4. doi: 10.1016/j.jinf.2023.
    >> Share

  172. LUNT R, Quinot C, Kirsebom F, Andrews N, et al
    The Impact of Vaccination and SARS-CoV-2 Variants on the Virological Response to SARS-CoV-2 Infections during the Alpha, Delta, and Omicron waves in England.
    J Infect. 2023 Nov 3:S0163-4453(23)00547-9. doi: 10.1016/j.jinf.2023.
    >> Share

    October 2023
  173. BRUHN M, Obara M, Chiyyeadu A, Costa B, et al
    Memory B cells anticipate SARS-CoV-2 variants through somatic hypermutation.
    J Infect. 2023 Oct 30:S0163-4453(23)00551-0. doi: 10.1016/j.jinf.2023.
    >> Share

  174. JIANG W, Xu L, Wang Y, Hao C, et al
    Exploring immunity debt: Dynamic alterations in RSV antibody levels in children under 5 years during the COVID-19 pandemic.
    J Infect. 2023 Oct 29:S0163-4453(23)00550-9. doi: 10.1016/j.jinf.2023.
    >> Share

  175. JIN Z, Wu J, Wang Y, Huang T, et al
    Safety and immunogenicity of the COVID-19 mRNA vaccine CS-2034: A randomized, double-blind, dose-exploration, placebo-controlled multicenter Phase I clinical trial in healthy Chinese adults.
    J Infect. 2023 Oct 26:S0163-4453(23)00543-1. doi: 10.1016/j.jinf.2023.
    >> Share

  176. HA L, Levian C, Greene N, Goldfarb I, et al
    Association between acceptance of routine pregnancy vaccinations and COVID-19 vaccine uptake in pregnant patients.
    J Infect. 2023 Oct 19:S0163-4453(23)00541-8. doi: 10.1016/j.jinf.2023.
    >> Share

  177. MARJANEH MM, Challenger JD, Salas A, Gomez-Carballa A, et al
    Analysis of blood and nasal epithelial transcriptomes to identify mechanisms associated with control of SARS-CoV-2 viral load in the upper respiratory tract.
    J Infect. 2023 Oct 18:S0163-4453(23)00540-6. doi: 10.1016/j.jinf.2023.
    >> Share

  178. FENWICK C, Turelli P, Duhoo Y, Lau K, et al
    Broadly potent anti-SARS-CoV-2 antibody shares 93% of epitope with ACE2 and provides full protection in monkeys.
    J Infect. 2023 Oct 16:S0163-4453(23)00539-X. doi: 10.1016/j.jinf.2023.
    >> Share

  179. LU XM, Feng XY, Wu Y, Wen CB, et al
    Genetic characterization of a novel H5N6 subtype highly pathogenic avian influenza virus from goose in China.
    J Infect. 2023 Oct 12:S0163-4453(23)00533-9. doi: 10.1016/j.jinf.2023.
    >> Share

  180. BEARD KR, Borca F, Phan H, Brown E, et al
    Routine, molecular point-of-care testing for SARS-CoV-2 and other respiratory viruses within an acute oncology service improves patient care.
    J Infect. 2023 Oct 4:S0163-4453(23)00514-5. doi: 10.1016/j.jinf.2023.
    >> Share

  181. TIAN S, Liu T, Zhao XJ, Liu XL, et al
    Neutralization against emerging Omicron subvariants after SARS-CoV-2 reinfection.
    J Infect. 2023 Oct 4:S0163-4453(23)00515-7. doi: 10.1016/j.jinf.2023.
    >> Share

    September 2023
  182. VELLAS C, Latour J, Tremeaux P, Ranger N, et al
    Molecular Evolution of Omicron Variant in Immunocompromised Individuals with Chronic SARS-CoV-2 Infection.
    J Infect. 2023 Sep 30:S0163-4453(23)00513-3. doi: 10.1016/j.jinf.2023.
    >> Share

  183. ANTONELLI M, Penfold RS, Canas LDS, Sudre C, et al
    SARS-CoV-2 infection following booster vaccination: illness and symptom profile in a prospective, observational community-based case-control study.
    J Infect. 2023 Sep 28:S0163-4453(23)00461-9. doi: 10.1016/j.jinf.2023.
    >> Share

  184. GAO Y, Zhang Y, Mou K, Man S, et al
    Alterations in the outer retina and choroid in patients after COVID-19 infection.
    J Infect. 2023 Sep 27:S0163-4453(23)00512-1. doi: 10.1016/j.jinf.2023.
    >> Share

  185. YAMAMOTO S, Mizoue T, Konishi M, Oshiro Y, et al
    Kinetics and durability of nucleocapsid-specific antibodies after SARS-CoV-2 reinfection.
    J Infect. 2023 Sep 26:S0163-4453(23)00511-X. doi: 10.1016/j.jinf.2023.
    >> Share

  186. SNOW TAC, Arulkumaran N, Singer M, Choi SH, et al
    Effect of dexamethasone dose on outcomes in acute COVID-19 disease: a systematic review and meta-analysis.
    J Infect. 2023 Sep 25:S0163-4453(23)00510-8. doi: 10.1016/j.jinf.2023.
    >> Share

  187. MATSUO OM, Lindoso L, Sousa Marques HH, Polanczyk GV, et al
    Mental health among children and adolescents after SARS-CoV-2 infection: a prospective study in a tertiary university hospital.
    J Infect. 2023 Sep 20:S0163-4453(23)00507-8. doi: 10.1016/j.jinf.2023.
    >> Share

  188. ALPIZAR SA, Accini J, Anderson DC, Eysa B, et al
    Molnupiravir for Intra-Household Prevention of COVID-19: the MOVe-AHEAD Randomized, Placebo-Controlled Trial.
    J Infect. 2023 Sep 8:S0163-4453(23)00500-5. doi: 10.1016/j.jinf.2023.
    >> Share

  189. CHEN JM, Tan SM, Chen RX, Gong HY, et al
    Distribution and risks of the infections of humans and other mammals with H5 subtype highly pathogenic avian influenza viruses in 2020-2023.
    J Infect. 2023 Sep 7:S0163-4453(23)00505-4. doi: 10.1016/j.jinf.2023.
    >> Share

  190. CLARK SA, Campbell H, Ribeiro S, Bertran M, et al
    Epidemiological and strain characteristics of invasive meningococcal disease prior to, during and after COVID-19 pandemic restrictions in England.
    J Infect. 2023 Sep 7:S0163-4453(23)00504-2. doi: 10.1016/j.jinf.2023.
    >> Share

  191. DOWELL AC, Tut G, Begum J, Bruton R, et al
    Nasal mucosal IgA levels against SARS-CoV-2 and seasonal coronaviruses are low in children but boosted by reinfection.
    J Infect. 2023 Sep 1:S0163-4453(23)00465-6. doi: 10.1016/j.jinf.2023.
    >> Share

    August 2023
  192. GUAN X, Huang Q, Dong M, Li M, et al
    SARS-CoV-2-specific antibody and T-cell immunity in convalescents after infection wave in Beijing in late 2022.
    J Infect. 2023 Aug 29:S0163-4453(23)00462-0. doi: 10.1016/j.jinf.2023.
    >> Share

  193. WHITAKER HJ, Tsang RS, Byford R, Aspden C, et al
    COVID-19 vaccine effectiveness against hospitalisation and death of people in clinical risk groups during the Delta variant period: English primary care network cohort study.
    J Infect. 2023 Aug 12:S0163-4453(23)00456-5. doi: 10.1016/j.jinf.2023.
    >> Share

  194. WAGENHAUSER I, Mees J, Reusch J, Lam TT, et al
    Determinants of Influenza A Infection Rate in Post-COVID-19 Era.
    J Infect. 2023 Aug 9:S0163-4453(23)00455-3. doi: 10.1016/j.jinf.2023.
    >> Share

  195. FAUSTINI SE, Cook A, Hill H, Al-Taei S, et al
    Saliva antiviral antibody levels are detectable but correlate poorly with serum antibody levels following SARS-CoV-2 infection and/or vaccination.
    J Infect. 2023 Aug 3:S0163-4453(23)00439-5. doi: 10.1016/j.jinf.2023.
    >> Share

    July 2023
  196. YAO XY, Lian CY, Lv ZH, Zhang XL, et al
    Emergence of a novel reassortant H5N6 subtype highly pathogenic avian influenza virus in farmed dogs in China.
    J Infect. 2023 Jul 26:S0163-4453(23)00386-9. doi: 10.1016/j.jinf.2023.
    >> Share

  197. SUN B, Gao F
    Investigation of escape mechanisms of SARS-CoV-2 Omicron sub-lineages and exploration of potential antibodies for XBB.1.
    J Infect. 2023 Jul 26:S0163-4453(23)00387-0. doi: 10.1016/j.jinf.2023.
    >> Share

  198. PIERANGELI A, Nenna R, Fracella M, Scagnolari C, et al
    Genetic diversity and its impact on disease severity in respiratory syncytial virus subtype-A and -B bronchiolitis before and after pandemic restrictions in Rome.
    J Infect. 2023 Jul 24:S0163-4453(23)00381-X. doi: 10.1016/j.jinf.2023.
    >> Share

  199. THEODOSIOU AA, Read RC
    Artificial Intelligence, Machine Learning and Deep Learning: Potential Resources for the Infection Clinician.
    J Infect. 2023 Jul 17:S0163-4453(23)00379-1. doi: 10.1016/j.jinf.2023.
    >> Share

  200. KAMBOJ M, Laracy JC, Usiak S, Babady NE, et al
    Outcomes of hematologic malignancy patients with SARS-CoV-2 breakthrough infections after tixagevimab-cilgavimab during community transmission of monoclonal antibody resistant variants.
    J Infect. 2023 Jul 13:S0163-4453(23)00378-X. doi: 10.1016/j.jinf.2023.
    >> Share

  201. FEELISCH M, Clark AD, Cumpstey AF, Santolini J, et al
    Long COVID: Potential role of the Reactive Species Interactome.
    J Infect. 2023 Jul 11:S0163-4453(23)00376-6. doi: 10.1016/j.jinf.2023.
    >> Share

  202. RISSMANN M, Veldhuis Kroeze EJB, Tielens AGM, Rockx B, et al
    Influence of a chronic Schistosoma mansoni infection on the outcomes of a SARS-CoV-2 infection in the hamster model.
    J Infect. 2023 Jul 5:S0163-4453(23)00374-2. doi: 10.1016/j.jinf.2023.
    >> Share

  203. BAYHAN GI, Guner R, Yahsi A, Ozkul A, et al
    Evaluation of the neutralizing antibody response against the omicron variant produced by heterologous or hybrid immunity: How does the fifth dose of COVID-19 vaccine affect the neutralizing antibody response?
    J Infect. 2023 Jul 4:S0163-4453(23)00369-9. doi: 10.1016/j.jinf.2023.
    >> Share

  204. TAUCHER C, Lazarus R, Dellago H, Maurer G, et al
    Safety and Immunogenicity against Ancestral, Delta and Omicron Virus Variants Following a Booster Dose of an Inactivated Whole-Virus COVID-19 Vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COM
    J Infect. 2023 Jul 3:S0163-4453(23)00367-5. doi: 10.1016/j.jinf.2023.
    >> Share

    June 2023
  205. VARASI I, Lai A, Fiaschi L, Bergna A, et al
    Neutralizing antibodies response to novel SARS-CoV-2 omicron sublineages in long-term care facility residents after the fourth dose of monovalent BNT162b2 COVID-19 vaccination.
    J Infect. 2023 Jun 30:S0163-4453(23)00342-0. doi: 10.1016/j.jinf.2023.
    >> Share

  206. WU JY, Hsu WH, Tsai YW, Liu TH, et al
    The association between zinc deficiency, and clinical outcomes of COVID-19.
    J Infect. 2023 Jun 29:S0163-4453(23)00343-2. doi: 10.1016/j.jinf.2023.
    >> Share

  207. DOWELL AC, Waiblinger D, Wright J, Ladhani SN, et al
    Nucleocapsid-Specific Antibodies as a Correlate of Protection against SARS-CoV-2 Reinfection in Children.
    J Infect. 2023 Jun 28:S0163-4453(23)00340-7. doi: 10.1016/j.jinf.2023.
    >> Share

  208. SU HC, Lai ZL, Chang YC, Cheng MY, et al
    Genomic characteristics of SARS-CoV-2 variants and their clinical impact on patients with COVID-19 in Taiwan.
    J Infect. 2023 Jun 27:S0163-4453(23)00341-9. doi: 10.1016/j.jinf.2023.
    >> Share

  209. HAGIYA H, Osaki Y, Yamamoto M, Niimura T, et al
    Global trends of seasonal influenza-associated mortality in 2001-2018: A longitudinal epidemiological study.
    J Infect. 2023 Jun 16:S0163-4453(23)00334-1. doi: 10.1016/j.jinf.2023.
    >> Share

  210. KELLY E, Greenland M, de Whalley PCS, Aley PK, et al
    Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A Randomised Controlled Trial.
    J Infect. 2023 Jun 16:S0163-4453(23)00330-4. doi: 10.1016/j.jinf.2023.
    >> Share

  211. STANKUNAS M, Dziugys A, Skarbalius G, Misiulis E, et al
    AUTHORS' REPLY TO A COMMENTARY ON THE POTENTIAL IMPACT OF COVID-19 PASSPORTS TO EPIDEMIOLOGICAL SITUATION.
    J Infect. 2023 Jun 15:S0163-4453(23)00333-X. doi: 10.1016/j.jinf.2023.
    >> Share

  212. FALLET B, Foglierini M, Porret R, Alcaraz A, et al
    Intradermal skin test with mRNA vaccines as a surrogate marker of T cell immunity in immunocompromised patients.
    J Infect. 2023 Jun 13:S0163-4453(23)00329-8. doi: 10.1016/j.jinf.2023.
    >> Share

  213. BISHARAT N, Campisi-Pinto S
    Determinants of reinfection with SARS-CoV-2 Omicron variant.
    J Infect. 2023 Jun 9:S0163-4453(23)00325-0. doi: 10.1016/j.jinf.2023.
    >> Share

  214. CAI J, Ruan J, Lin Q, Ren T, et al
    China faces the challenge of influenza A virus, including H3N8, in the post-COVID-19 era.
    J Infect. 2023 Jun 7:S0163-4453(23)00324-9. doi: 10.1016/j.jinf.2023.
    >> Share

  215. MOHN KG, Bredholt G, Onyango TB, Brokstad KA, et al
    SARS-CoV-2 infection induces long-lived B and T-cell responses up to 15 months post-infection, irrespective of disease severity.
    J Infect. 2023 Jun 7:S0163-4453(23)00302-X. doi: 10.1016/j.jinf.2023.
    >> Share

  216. PASCALL DJ, Vink E, Blacow R, Bulteel N, et al
    Directions of change in intrinsic case severity across successive SARS-CoV-2 variant waves have been inconsistent.
    J Infect. 2023 Jun 1:S0163-4453(23)00297-9. doi: 10.1016/j.jinf.2023.
    >> Share

    May 2023
  217. LIU P, Cheng F, Su L, Ye Z, et al
    An outbreak of influenza A in Shanghai after ending the zero-COVID policy in February-March 2023.
    J Infect. 2023 May 27:S0163-4453(23)00301-8. doi: 10.1016/j.jinf.2023.
    >> Share

  218. NG RW, Sze RK, Chong KC, Zhao S, et al
    Effectiveness of mRNA and inactivated COVID-19 vaccines: a test-negative study in an infection-naive Hong Kong population.
    J Infect. 2023 May 26:S0163-4453(23)00298-0. doi: 10.1016/j.jinf.2023.
    >> Share

  219. ZHAO T, Li Y, Xu M, Wang W, et al
    High proportion of H3 avian influenza virus circulating in chickens-an increasing threat to public health.
    J Infect. 2023 May 24:S0163-4453(23)00296-7. doi: 10.1016/j.jinf.2023.
    >> Share

  220. FAVRESSE J, Cabo J, Douxfils J
    Cellular immunity against SARS-CoV-2 is predominantly boosted in vaccinated individuals with no history of infection.
    J Infect. 2023 May 19:S0163-4453(23)00292-X. doi: 10.1016/j.jinf.2023.
    >> Share

  221. DIAN Y, Meng Y, Sun Y, Deng G, et al
    Azvudine versus Paxlovid for oral treatment of COVID-19 in Chinese patients with pre-existing comorbidities.
    J Infect. 2023 May 17:S0163-4453(23)00290-6. doi: 10.1016/j.jinf.2023.
    >> Share

  222. NAOURI D, Pham T, Dres M, Vuagnat A, et al
    Differences in clinical characteristics and outcomes between COVID-19 and influenza in critically ill adult patients: a national database study.
    J Infect. 2023 May 16:S0163-4453(23)00289-X. doi: 10.1016/j.jinf.2023.
    >> Share

  223. ZHONG X, Pate A, Yang YT, Fahmi A, et al
    The impact of COVID -19 on antibiotic prescribing in primary care in England: evaluation and risk prediction of appropriateness of type and repeat prescribing.
    J Infect. 2023 May 12:S0163-4453(23)00288-8. doi: 10.1016/j.jinf.2023.
    >> Share

  224. PINANA M, Gonzalez-Sanchez A, Andres C, Abanto M, et al
    The emergence, impact, and evolution of human metapneumovirus variants from 2014 to 2021 in Spain.
    J Infect. 2023 May 11:S0163-4453(23)00262-1. doi: 10.1016/j.jinf.2023.
    >> Share

  225. LV W, He J, Shao J, Chen Y, et al
    Causal relationships between short-chain fatty acids and L-isoleucine biosynthesis and susceptibility and severity of COVID-19: Evidence from Mendelian randomization.
    J Infect. 2023 May 5:S0163-4453(23)00258-X. doi: 10.1016/j.jinf.2023.
    >> Share

  226. GAO M, Ao G, Hao X, Xie B, et al
    Casirivimab-Imdevimab treatment is associated with reduced rates of mortality and hospitalization in patients with COVID-19: A systematic review with meta-analysis.
    J Infect. 2023 May 3:S0163-4453(23)00256-6. doi: 10.1016/j.jinf.2023.
    >> Share

    April 2023
  227. XU J, Mao D, Liang P, Du P, et al
    Undetectable intrauterine transmission during the first trimester of pregnancy in woman after COVID-19 infection.
    J Infect. 2023 Apr 26:S0163-4453(23)00255-4. doi: 10.1016/j.jinf.2023.
    >> Share

  228. AWAN UA, Hussain M, Qureshi M, Siddique Z, et al
    From COVID-19 to Measles: Prioritizing Immunization in Pakistan's Far-Flung Regions.
    J Infect. 2023 Apr 26:S0163-4453(23)00253-0. doi: 10.1016/j.jinf.2023.
    >> Share

  229. ZHOU Y, Yan H, Zhou Q, Feng R, et al
    Impact of COVID-19 control measures on Legionella pneumophila infections in children in Henan, China.
    J Infect. 2023 Apr 26:S0163-4453(23)00254-2. doi: 10.1016/j.jinf.2023.
    >> Share

  230. AZIZ NA, Nash SG, Zaidi A, Nyberg T, et al
    Risk of severe outcomes among SARS-CoV-2 Omicron BA.4 and BA.5 cases compared to BA.2 cases in England.
    J Infect. 2023 Apr 24:S0163-4453(23)00249-9. doi: 10.1016/j.jinf.2023.
    >> Share

  231. FURUSE Y
    Estimation of excess cardiovascular deaths after COVID-19 in 2020.
    J Infect. 2023 Apr 24:S0163-4453(23)00251-7. doi: 10.1016/j.jinf.2023.
    >> Share

  232. LIU X, Munro APS, Wright A, Feng S, et al
    Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial.
    J Infect. 2023 Apr 19:S0163-4453(23)00247-5. doi: 10.1016/j.jinf.2023.
    >> Share

  233. LUO J, Li A, Liu C, Wang Y, et al
    The effect of bebtelovimab on clinical outcomes in patients with COVID-19: a meta-analysis.
    J Infect. 2023 Apr 19:S0163-4453(23)00210-4. doi: 10.1016/j.jinf.2023.
    >> Share

  234. WEN F, Chen G, Guo J, Guan M, et al
    Identification of a duck H9N2 influenza virus possessing tri-basic hemagglutinin cleavage sites genetically close to the human H9N2 isolates in China, 2022.
    J Infect. 2023 Apr 17:S0163-4453(23)00207-4. doi: 10.1016/j.jinf.2023.
    >> Share

  235. PIGHI L, Henry BM, De Nitto S, Salvagno GL, et al
    Cellular immunity against SARS-CoV-2 depends on the serological status.
    J Infect. 2023 Apr 13:S0163-4453(23)00203-7. doi: 10.1016/j.jinf.2023.
    >> Share

  236. TEYSSOU E, Marot S, Gothland A, Malet I, et al
    SARS-CoV-2 variant-dependent inflammasome activation.
    J Infect. 2023 Apr 13:S0163-4453(23)00205-0. doi: 10.1016/j.jinf.2023.
    >> Share

  237. MORRISON H, Perrin F, Dedicoat M, Ahmed R, et al
    Impact of COVID-19 on NHS Tuberculosis Services: Results of a UK-wide survey.
    J Infect. 2023 Apr 10:S0163-4453(23)00204-9. doi: 10.1016/j.jinf.2023.
    >> Share

  238. SHAW RH, Greenland M, Stuart AS, Aley PK, et al
    Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - a single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines.
    J Infect. 2023 Apr 5:S0163-4453(23)00199-8. doi: 10.1016/j.jinf.2023.
    >> Share

  239. ZHAO D, Yi H, Dian Y, Meng Y, et al
    Elevated troponin levels predict the reduced efficacy of Paxlovid in COVID-19 patients.
    J Infect. 2023 Apr 3:S0163-4453(23)00200-1. doi: 10.1016/j.jinf.2023.
    >> Share

  240. CHEN H, Zhang L, Zhang Y, Chen G, et al
    Prevalence and clinical features of long COVID from omicron infection in children and adults.
    J Infect. 2023;86:e97-e99.
    >> Share

    March 2023
  241. GAO Y, Luo Z, Ren S, Duan Z, et al
    Antiviral effect of azvudine and nirmatrelvir-ritonavir among hospitalized patients with COVID-19.
    J Infect. 2023 Mar 30:S0163-4453(23)00192-5. doi: 10.1016/j.jinf.2023.
    >> Share

  242. KELLENI MT
    SARS CoV-2 Genetic Jump to a New SARS CoV-3 Pandemic: Let's Be Prepared.
    J Infect. 2023 Mar 21:S0163-4453(23)00147-0. doi: 10.1016/j.jinf.2023.
    >> Share

  243. NAMGUNG SH, Jung J, Kim SK, Kim EO, et al
    Incidence of tuberculosis infection in healthcare workers in high-risk departments for tuberculosis after universal wearing of KF94 mask during COVID-19 pandemic.
    J Infect. 2023 Mar 21:S0163-4453(23)00146-9. doi: 10.1016/j.jinf.2023.
    >> Share

  244. HSU WH, Shiau BW, Tsai YW, Wu JY, et al
    The effect of molnupiravir on post-acute outcome of COVID-19 survivors.
    J Infect. 2023 Mar 21:S0163-4453(23)00145-7. doi: 10.1016/j.jinf.2023.
    >> Share

  245. DANIAL-FARRAN N, Khlaila M, Avraham-Kelbert M, Chazan B, et al
    Genetic Variant in Complement Receptor 1 (CR1, CD35) is Associated with A Cluster of Severe Fatal COVID-19 in a Family.
    J Infect. 2023 Mar 14:S0163-4453(23)00143-3. doi: 10.1016/j.jinf.2023.
    >> Share

  246. CLARK TW, Lindsley K, Wigmosta TB, Bhagat A, et al
    Rapid Multiplex PCR for Respiratory Viruses Reduces Time to Result and Improves Clinical Care: Results of a Systematic Review and Meta-Analysis.
    J Infect. 2023 Mar 9:S0163-4453(23)00134-2. doi: 10.1016/j.jinf.2023.
    >> Share

  247. SHAO JW, Zhang XL, Sun J, Liu H, et al
    Infection of wild rats with H5N6 subtype highly pathogenic avian influenza virus in China.
    J Infect. 2023 Mar 7:S0163-4453(23)00136-6. doi: 10.1016/j.jinf.2023.
    >> Share

  248. WANG H, Liu Y, Li P, Liu C, et al
    Emergence of epidemic variants of SARS-CoV-2 by acquiring combinations of new highly mutable nucleotides in its genome.
    J Infect. 2023 Mar 6:S0163-4453(23)00133-0. doi: 10.1016/j.jinf.2023.
    >> Share

  249. QUILES-JIMENEZ A, Sousa M, Huse C, Dyrhol-Riise AM, et al
    Severely-ill COVID-19 patients have altered circulating levels of proteins controlling the epitranscriptome.
    J Infect. 2023 Mar 6:S0163-4453(23)00132-9. doi: 10.1016/j.jinf.2023.
    >> Share

  250. SIVAKUMARAN S, Alsallakh MA, Lyons RA, Quint JK, et al
    Estimating the contribution of respiratory pathogens to acute exacerbations of COPD using routine data.
    J Infect. 2023;86:233-238.
    >> Share

  251. LIU P, Xu J
    Genomic surveillance of SARS-CoV-2 in mainland China after ending the zero-COVID policy, December 2022 - January 2023.
    J Infect. 2023 Mar 1:S0163-4453(23)00127-5. doi: 10.1016/j.jinf.2023.
    >> Share

    February 2023
  252. SCARPA F, Imperia E, Azzena I, Giovanetti M, et al
    Genetic and structural genome-based survey reveals the low potential for epidemiological expansion of the SARS-CoV-2 XBB.1.5 sublineage.
    J Infect. 2023 Feb 28:S0163-4453(23)00126-3. doi: 10.1016/j.jinf.2023.
    >> Share

  253. SHAVA E, Izu A, Gaolathe T, Walker A, et al
    Safety and incidence of COVID-19 following ChAdOx1(AZD1222) COVID-19 vaccination in Botswana.
    J Infect. 2023 Feb 28:S0163-4453(23)00123-8. doi: 10.1016/j.jinf.2023.
    >> Share

  254. DENG Y, Han S, Liu J, Guo L, et al
    The risks of death and hospitalizations associated with SARS-CoV-2 Omicron declined after lifting testing and quarantining measures.
    J Infect. 2023 Feb 27:S0163-4453(23)00118-4. doi: 10.1016/j.jinf.2023.
    >> Share

  255. ZHOU P, Gong F, Ji T, Cao C, et al
    Enriched CXCR3(+) CXCR5(+) CD8(+) T cells in SARS-CoV-2 infected and vaccinated individuals effectively respond to the antigen in recall.
    J Infect. 2023 Feb 23:S0163-4453(23)00109-3. doi: 10.1016/j.jinf.2023.
    >> Share

  256. GUO H, Zhao T
    Multiple mutations of IFITM3 are associated with COVID-19 susceptibility.
    J Infect. 2023 Feb 23:S0163-4453(23)00120-2. doi: 10.1016/j.jinf.2023.
    >> Share

  257. YANG F, Zhang N, Meng R, Wang K, et al
    Non-causal Association of COVID-19 with Systemic Lupus Erythematosus: Evidence from a Bidirectional Mendelian RandomizationRunning title: Association of COVID-19 with SLE.
    J Infect. 2023 Feb 21:S0163-4453(23)00115-9. doi: 10.1016/j.jinf.2023.
    >> Share

  258. UELAND T, Aikas LAO, Dahl TB, Gregersen I, et al
    Low-Density Lipoprotein Particles Carrying Proinflammatory Proteins with Altered Aggregation Pattern Detected in COVID-19 Patients 3 Months After HospitalizationRunning title: Low-Density Lipoprotein Particles in COVID-19 Patients.
    J Infect. 2023 Feb 21:S0163-4453(23)00111-1. doi: 10.1016/j.jinf.2023.
    >> Share

  259. PUTRI DU, Huang CK, Ou TY, Lin CF, et al
    Persistent dysregulation of cellular immunity following COVID-19 recovery despite minimal post-COVID-19 sequelae manifestationRunning title: Occult post-COVID immune dysregulation.
    J Infect. 2023 Feb 21:S0163-4453(23)00112-3. doi: 10.1016/j.jinf.2023.
    >> Share

  260. ZHANG K, Chen R, Jiang Q
    Allopurinol Increased the Risk of COVID-19 Hospitalization Mediated by E-Selectin Downregulation.
    J Infect. 2023 Feb 21:S0163-4453(23)00116-0. doi: 10.1016/j.jinf.2023.
    >> Share

  261. MEI R, Kwok SLL, Lau EHY, Lo THK, et al
    Battle of Polio eradication in the Western Pacific Region in the transition to COVID-19 endemicity.
    J Infect. 2023 Feb 21:S0163-4453(23)00113-5. doi: 10.1016/j.jinf.2023.
    >> Share

  262. WAN EYF, Wang B, Mathur S, Chan CIY, et al
    Molnupiravir and nirmatrelvir-ritonavir reduce mortality risk during post-acute COVID-19 phase.
    J Infect. 2023 Feb 21:S0163-4453(23)00117-2. doi: 10.1016/j.jinf.2023.
    >> Share

  263. VALENTINI D, Carfi A, Di Paola A, Yarci-Carrion A, et al
    Factor associated with SARS-CoV-2 vaccination serological efficacy in adolescents and adults with Down syndrome: data from an international, collaborative initiative of the Trisomy 21 Research SocietyRUNNING TITLE: Factors determining COVID-19 vaccine
    J Infect. 2023 Feb 20:S0163-4453(23)00090-7. doi: 10.1016/j.jinf.2023.
    >> Share

  264. POWELL AA, Ireland G, Leeson R, Lacey A, et al
    National and regional prevalence of SARS-CoV-2 antibodies in primary and secondary school children in England: the School Infection Survey, a national open cohort study, November 2021.
    J Infect. 2023 Feb 15:S0163-4453(23)00085-3. doi: 10.1016/j.jinf.2023.
    >> Share

  265. BIRD PW, Pan D, Martin CA, Gogoi M, et al
    Awareness of HIV, Hepatitis B, Hepatitis C, Tuberculosis and COVID-19 in Migrant Students in the UK - A Pilot Survey from an Institute of Higher Education.
    J Infect. 2023 Feb 14:S0163-4453(23)00086-5. doi: 10.1016/j.jinf.2023.
    >> Share

  266. ZHANG W, Sun M, Zhang P, Liang Y, et al
    Epidemiological characteristics of Cytomegalovirus infection in children before and after the COVID-19 pandemic in Henan, China, 2016 - 2022.
    J Infect. 2023 Feb 10:S0163-4453(23)00081-6. doi: 10.1016/j.jinf.2023.
    >> Share

  267. MENG R, Zhang N, Yang F, Xu Z, et al
    Blood Transcriptome Analysis Revealed the Crosstalk Between Severe COVID-19 and Systemic Lupus Erythematosus.
    J Infect. 2023 Feb 10:S0163-4453(23)00080-4. doi: 10.1016/j.jinf.2023.
    >> Share

  268. HSU WH, Tsai YW, Wu JY, Liu TH, et al
    Post-acute hospitalization and mortality of nirmatrelvir plus ritonavir for COVID-19 survivors.
    J Infect. 2023 Feb 9:S0163-4453(23)00076-2. doi: 10.1016/j.jinf.2023.
    >> Share

  269. EVANS A, Qi C, Adebayo JO, Underwood J, et al
    Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales: a retrospective cohort study.
    J Infect. 2023 Feb 9:S0163-4453(23)00082-8. doi: 10.1016/j.jinf.2023.
    >> Share

  270. LI L, Song X, Sun H, Ma J, et al
    Changes of pathogen distribution in children with wound infections before and after the COVID-19 pandemic in Henan, China.
    J Infect. 2023 Feb 9:S0163-4453(23)00079-8. doi: 10.1016/j.jinf.2023.
    >> Share

  271. HU S, Zhang S, You Y, Tang J, et al
    Olfactory dysfunction after COVID-19; metanalysis reveals persistence in one third of patients six months after initial infection.
    J Infect. 2023 Feb 9:S0163-4453(23)00068-3. doi: 10.1016/j.jinf.2023.
    >> Share

  272. LI R, Wang M, Li D, Zhang Y, et al
    The impact of the COVID-19 pandemic on the number of hand, foot, and mouth disease due to enterovirus 71 infections.
    J Infect. 2023 Feb 8:S0163-4453(23)00075-0. doi: 10.1016/j.jinf.2023.
    >> Share

  273. CAILLARD S, Laugel E, Benotmane I, Kremer SF, et al
    Molecular evolution of the SARS-CoV-2 omicron BA.2 variant in kidney transplant recipients with prolonged viral shedding.
    J Infect. 2023 Feb 8:S0163-4453(23)00070-1. doi: 10.1016/j.jinf.2023.
    >> Share

    January 2023
  274. AMANO M, Ichikawa Y, Uemura Y, Matsumoto S, et al
    Comparison of neutralization activity against Omicron BA.2/BA.5 in sera from HCWs receiving heterologous/homologous COVID-19 vaccines.
    J Infect. 2023 Jan 31:S0163-4453(23)00066-X. doi: 10.1016/j.jinf.2023.
    >> Share

  275. LIANG J, Liu R, He W, Zeng Z, et al
    70% COVID-19 infection within three weeks in the population of Macao, China.
    J Infect. 2023 Jan 30:S0163-4453(23)00035-X. doi: 10.1016/j.jinf.2023.
    >> Share

  276. CHANG YH, Liu TH, Wu JY, Lai CC, et al
    The association between corticosteroids and aspergillosis among COVID-19 patients.
    J Infect. 2023 Jan 27:S0163-4453(23)00055-5. doi: 10.1016/j.jinf.2023.
    >> Share

  277. RANA MS, Usman M, Alam MM, Tahir M, et al
    The emergence of Mumps after the COVID-19 Pandemic in Pakistan: time to consider MMR vaccination strategies.
    J Infect. 2023 Jan 26:S0163-4453(23)00057-9. doi: 10.1016/j.jinf.2023.
    >> Share

  278. NISAR MI, Ansari N, Malik AA, Shahid S, et al
    Assessing the effectiveness of COVID-19 vaccines in Pakistan: a test-negative case-control study.
    J Infect. 2023 Jan 25:S0163-4453(23)00021-X. doi: 10.1016/j.jinf.2023.
    >> Share

  279. HANI E, Bertran M, Powell A, Williams H, et al
    Significantly lower infection fatality rates associated with SARS-CoV-2 Omicron (B.1.1.529) infection in children and young people: active, prospective national surveillance, January-March 2022, England.
    J Infect. 2023 Jan 24:S0163-4453(23)00037-3. doi: 10.1016/j.jinf.2023.
    >> Share

  280. GENTRY CA, Nguyen P, Thind SK, Kurdgelashvili G, et al
    Characteristics and outcomes of US Veterans at least 65 years of age at high risk of severe SARS-CoV-2 infection with or without receipt of oral antiviral agents.
    J Infect. 2023 Jan 23:S0163-4453(23)00023-3. doi: 10.1016/j.jinf.2023.
    >> Share

  281. KELLENI MT
    Evolution of SARS CoV-2 Omicron Subvariants BF.7 and XBB.1.5: Time to follow Africa and abort all COVID Restrictions.
    J Infect. 2023 Jan 23:S0163-4453(23)00030-0. doi: 10.1016/j.jinf.2023.
    >> Share

  282. WU JY, Liu TH, Huang PY, Tsai YW, et al
    The effect of zinc on the outcome of patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials.
    J Infect. 2023 Jan 21:S0163-4453(23)00028-2. doi: 10.1016/j.jinf.2023.
    >> Share

  283. ZHAN H, Yang L, Liu Y, Li H, et al
    Acceptance, safety and immunogenicity of a booster dose of inactivated SARS-CoV-2 vaccine in adults with tuberculosis.
    J Infect. 2023 Jan 21:S0163-4453(23)00034-8. doi: 10.1016/j.jinf.2023.
    >> Share

  284. LIU X, Lv Z, Wang J, Zhou Y, et al
    IL1RA Mediated the Effects of Aspirin on Covid-19 severity: a Mendelian Randomization Study.
    J Infect. 2023 Jan 20:S0163-4453(23)00031-2. doi: 10.1016/j.jinf.2023.
    >> Share

  285. LIANG Y, Hou L, Hou G, Zhang X, et al
    The influences of the COVID-19 pandemic on Epstein-Barr virus infection in children, Henan, China.
    J Infect. 2023 Jan 20:S0163-4453(23)00026-9. doi: 10.1016/j.jinf.2023.
    >> Share

  286. SALTO-ALEJANDRE S, Carretero-Ledesma M, Camacho-Martinez P, Berastegui-Cabrera J, et al
    Serum IFN-gamma and RNAemia temporal profiles as biomarkers of severe COVID-19 in solid organ transplant and immunocompetent patients.
    J Infect. 2023 Jan 20:S0163-4453(23)00024-5. doi: 10.1016/j.jinf.2023.
    >> Share

  287. KANG SW, Kim JW, Kim JY, Lim SY, et al
    Characteristics and risk factors of prolonged viable virus shedding in immunocompromised patients with COVID-19: a prospective cohort study.
    J Infect. 2023 Jan 19:S0163-4453(23)00029-4. doi: 10.1016/j.jinf.2023.
    >> Share

  288. RANA MS, Usman M, Alam MM, Tahir M, et al
    Changes in the prevalence of infectious diseases before and after the COVID-19 pandemic in Pakistan.
    J Infect. 2023 Jan 19:S0163-4453(23)00025-7. doi: 10.1016/j.jinf.2023.
    >> Share

  289. RU X, Chen S, Zhang T, Ding Z, et al
    Nonpharmaceutical intervention is an effective measure to block respiratory virus coinfections with SARS-CoV-2.
    J Infect. 2023 Jan 18:S0163-4453(23)00018-X. doi: 10.1016/j.jinf.2023.
    >> Share

  290. SHAH RA, Mentzer AJ, James T, Cox S, et al
    A novel near-patient host-protein score predicts COVID-19 deterioration at presentation to secondary care.
    J Infect. 2023 Jan 18:S0163-4453(23)00022-1. doi: 10.1016/j.jinf.2023.
    >> Share

  291. KANG SW, Park H, Kim JY, Lim SY, et al
    Comparison of the clinical and virological characteristics of SARS-CoV-2 Omicron BA.1/BA.2 and omicron BA.5 variants: A prospective cohort study.
    J Infect. 2023 Jan 18:S0163-4453(23)00020-8. doi: 10.1016/j.jinf.2023.
    >> Share

  292. LIU TH, Wu JY, Huang PY, Tsai YW, et al
    The effect of nirmatrelvir plus ritonavir on the long-term risk of epilepsy and seizure following COVID-19: A retrospective cohort study including 91,528 patients.
    J Infect. 2023 Jan 14:S0163-4453(23)00017-8. doi: 10.1016/j.jinf.2023.
    >> Share

  293. LI X, Li T, Chen N, Kang P, et al
    Changes of Mycoplasma pneumoniae infection in children before and after COVID-19 pandemic in Henan, China.
    J Infect. 2023 Jan 13:S0163-4453(23)00012-9. doi: 10.1016/j.jinf.2022.
    >> Share

  294. DING X, Liang H, Qi X, Sun G, et al
    Changes of Klebsiella pneumoniae infection and carbapenem resistance in ICU elderly infected patients before and after the COVID-19 pandemic in Zhengzhou, China.
    J Infect. 2023 Jan 9:S0163-4453(23)00009-9. doi: 10.1016/j.jinf.2023.
    >> Share

  295. XU J, Wang Y, Duan G, Liu F, et al
    Impact of non-pharmaceutical interventions during COVID-19 pandemic on measles and mumps in mainland China.
    J Infect. 2023 Jan 9:S0163-4453(23)00008-7. doi: 10.1016/j.jinf.2023.
    >> Share

  296. PATIL S, Chen H, Dong S, Liu S, et al
    Klebsiella pneumoniae infection in the paediatric population before and after the COVID-19 pandemic in Shenzhen, China.
    J Infect. 2023 Jan 8:S0163-4453(23)00004-X. doi: 10.1016/j.jinf.2023.
    >> Share

  297. LI Y, Liang H, Ding X, Cao Y, et al
    Effectiveness of COVID-19 vaccine in children and adolescents with the Omicron variant: A systematic review and meta-analysis.
    J Infect. 2023 Jan 6:S0163-4453(23)00001-4. doi: 10.1016/j.jinf.2023.
    >> Share

  298. YU Z, Xu S, Li L, Li M, et al
    Changes of Cytomegalovirus infection in neonates before and after the COVID19 pandemic in Zhengzhou, China.
    J Infect. 2023 Jan 5:S0163-4453(23)00002-6. doi: 10.1016/j.jinf.2023.
    >> Share

  299. ZHAO S, Sha T, Xue Y, Chen H, et al
    Flattening the Curve is Imperative: When China Relaxes the Dynamic Zero COVID-19 Policy.
    J Infect. 2023 Jan 2:S0163-4453(22)00748-4. doi: 10.1016/j.jinf.2022.
    >> Share

  300. CAMACHO J, Zulaica J, Gimenez E, Rusu L, et al
    Neutralizing antibodies against Omicron BA.4/5 after COVID-19 vaccination in SARS-CoV-2 experienced versus naive individuals in the general population.
    J Infect. 2023 Jan 1:S0163-4453(22)00755-1. doi: 10.1016/j.jinf.2022.
    >> Share

    December 2022
  301. CILLONIZ C, Motos A, Castaneda T, Gabarrus A, et al
    Remdesivir and survival outcomes in critically ill patients with COVID-19: A multicentre observational cohort study.
    J Infect. 2022 Dec 31:S0163-4453(22)00753-8. doi: 10.1016/j.jinf.2022.
    >> Share

  302. LIANG Y, Li J, Hou L, Zhang X, et al
    Changes of Staphylococcus aureus infection in children before and after the COVID-19 pandemic, Henan, China.
    J Infect. 2022 Dec 28:S0163-4453(22)00751-4. doi: 10.1016/j.jinf.2022.
    >> Share

  303. FERNANDEZ-DE-LAS-PENAS C, Arendt-Nielsen L, Diaz-Gil G, Gil-Crujera A, et al
    ACE1 rs1799752 Polymorphism is not Associated with Long-COVID Symptomatology in Previously Hospitalized COVID-19 Survivors.
    J Infect. 2022 Dec 27:S0163-4453(22)00752-6. doi: 10.1016/j.jinf.2022.
    >> Share

  304. LI Y, Cao Y, Ding X, Yang D, et al
    Influence of the COVID-19 pandemic on Staphylococcus aureus bloodstream infection in children, Henan, China.
    J Infect. 2022 Dec 25:S0163-4453(22)00746-0. doi: 10.1016/j.jinf.2022.
    >> Share

  305. SCHILDGEN O, Lusebrink J, Schildgen V
    Recommendation for broad use of Covid-19 mRNA vaccine boosters due to waning vaccine effectiveness is taking the easy way out.
    J Infect. 2022 Dec 24:S0163-4453(22)00744-7. doi: 10.1016/j.jinf.2022.
    >> Share

  306. KRONE M, Wagenhauser I, Knies K, Hofmann D, et al
    Clinical accuracy of SARS-CoV-2 rapid antigen testing in screening children and adolescents.
    J Infect. 2022 Dec 21:S0163-4453(22)00740-X. doi: 10.1016/j.jinf.2022.
    >> Share

  307. JANKUNAS R, Sakalauskas L, Zamaryte-Sakaviciene K, Stakisaitis D, et al
    COMMENTARY ON THE IMPACT OF THE COVID-19 PASSPORTS IN LITHUANIA.
    J Infect. 2022 Dec 20:S0163-4453(22)00703-4. doi: 10.1016/j.jinf.2022.
    >> Share

  308. C O, H W, R B, E L, et al
    Following the Omicron wave, the majority of children in England have evidence of previous COVID infection.
    J Infect. 2022 Dec 18:S0163-4453(22)00701-0. doi: 10.1016/j.jinf.2022.
    >> Share

  309. LI X, Peng K, Cheng FW, Lam DC, et al
    Tuberculosis following two-dose SARS-CoV-2 vaccination with messenger RNA vaccine (BNT162b2) and inactivated virus vaccine (CoronaVac).
    J Infect. 2022 Dec 17:S0163-4453(22)00706-X. doi: 10.1016/j.jinf.2022.
    >> Share

  310. LIANG Y, Zhang P, Du B, Zhang X, et al
    Changes of Mycoplasma pneumoniae infection in children before and after the COVID - 19 pandemic, Henan, China.
    J Infect. 2022 Dec 15:S0163-4453(22)00705-8. doi: 10.1016/j.jinf.2022.
    >> Share

  311. CHENG P, Li L, Sun H, Zhu C, et al
    Changes of pathogen distribution in children with bacterial meningitis before and after the COVID-19 pandemic in Zhengzhou, China.
    J Infect. 2022 Dec 10:S0163-4453(22)00696-X. doi: 10.1016/j.jinf.2022.
    >> Share

  312. JIANG L, Tang L, Zhu L, Zhu Y, et al
    Viral dynamics during SARS-CoV-2 omicron infection highlight presymptomatic and asymptomatic infectiousness.
    J Infect. 2022 Dec 1:S0163-4453(22)00687-9. doi: 10.1016/j.jinf.2022.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016